Glukokortikoidinduceret diabetes og risikofaktorer under højdosisbehandling

Dustin Andersen Patel; Peter Lommer Kristensen; Ulrik Pedersen-Bjergaard; Helga Holm Schultz

Glukokortikoidinduceret diabetes og risikofaktorer under højdosisbehandling

Translated title of the contribution: Glucocorticoid-induced diabetes and risk factors during high-dose therapy

Dustin Andersen Patel, Peter Lommer Kristensen, Ulrik Pedersen-Bjergaard, Helga Holm Schultz

Department of Clinical Medicine

1 Citation (Scopus)

Abstract

This review describes the cumulative incidence (CI) and risk factors of glucocorticoid (GC)-induced diabetes in patients commencing high-dose GC therapy: ≥ 30 mg prednisolone/day. Finally, methods of screening are discussed. In 13 studies, the CI of GC-induced diabetes ranges 12-65%, but with the current diagnostic criteria the CI is assessed to be 30-50%. Risk factors may include high age and high levels of BMI and glycated haemoglobin, respectively, before GC therapy. It is important to acknowledge, that hyperglycaemia in GC therapy is more prevalent postprandially, and screening should be planned accordingly.

Translated title of the contribution	Glucocorticoid-induced diabetes and risk factors during high-dose therapy
Original language	Danish
Article number	V06170454
Journal	Ugeskrift for Laeger
Volume	180
Number of pages	6
ISSN	0041-5782
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/glukokortikoidinduceret-diabetes-og-risikofaktorer-under-hoejdosisbehandling

Cite this

@article{f0cc1035c794479cb37e101c0dfffe4a,

title = "Glukokortikoidinduceret diabetes og risikofaktorer under h{\o}jdosisbehandling",

abstract = "This review describes the cumulative incidence (CI) and risk factors of glucocorticoid (GC)-induced diabetes in patients commencing high-dose GC therapy: ≥ 30 mg prednisolone/day. Finally, methods of screening are discussed. In 13 studies, the CI of GC-induced diabetes ranges 12-65%, but with the current diagnostic criteria the CI is assessed to be 30-50%. Risk factors may include high age and high levels of BMI and glycated haemoglobin, respectively, before GC therapy. It is important to acknowledge, that hyperglycaemia in GC therapy is more prevalent postprandially, and screening should be planned accordingly.",

author = "Patel, {Dustin Andersen} and Kristensen, {Peter Lommer} and Ulrik Pedersen-Bjergaard and Schultz, {Helga Holm}",

year = "2018",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Glukokortikoidinduceret diabetes og risikofaktorer under højdosisbehandling

AU - Patel, Dustin Andersen

AU - Kristensen, Peter Lommer

AU - Pedersen-Bjergaard, Ulrik

AU - Schultz, Helga Holm

PY - 2018

Y1 - 2018

N2 - This review describes the cumulative incidence (CI) and risk factors of glucocorticoid (GC)-induced diabetes in patients commencing high-dose GC therapy: ≥ 30 mg prednisolone/day. Finally, methods of screening are discussed. In 13 studies, the CI of GC-induced diabetes ranges 12-65%, but with the current diagnostic criteria the CI is assessed to be 30-50%. Risk factors may include high age and high levels of BMI and glycated haemoglobin, respectively, before GC therapy. It is important to acknowledge, that hyperglycaemia in GC therapy is more prevalent postprandially, and screening should be planned accordingly.

AB - This review describes the cumulative incidence (CI) and risk factors of glucocorticoid (GC)-induced diabetes in patients commencing high-dose GC therapy: ≥ 30 mg prednisolone/day. Finally, methods of screening are discussed. In 13 studies, the CI of GC-induced diabetes ranges 12-65%, but with the current diagnostic criteria the CI is assessed to be 30-50%. Risk factors may include high age and high levels of BMI and glycated haemoglobin, respectively, before GC therapy. It is important to acknowledge, that hyperglycaemia in GC therapy is more prevalent postprandially, and screening should be planned accordingly.

M3 - Tidsskriftartikel

C2 - 29720341

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V06170454

ER -

Glukokortikoidinduceret diabetes og risikofaktorer under højdosisbehandling

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this